Affordable Access

deepdyve-link
Publisher Website

[Classification and morbidity of debulking surgery for advanced ovarian cancer].

Authors
  • Vincens, E
  • Lauratet, B
  • Lefranc, J-P
Type
Published Article
Journal
Bulletin du Cancer
Publisher
Elsevier
Publication Date
Jan 01, 2010
Volume
97
Issue
1
Pages
73–77
Identifiers
DOI: 10.1684/bdc.2010.1015
PMID: 20080457
Source
Medline
License
Unknown

Abstract

Postoperative residual disease is a major predicting factor in the treatment of advanced ovarian cancer. The goal of the surgery is now well known. It is to eradicate all macroscopic tumor. So, the most useful way to describe the residual disease is to measure exactly the size of the tumor left after surgery (no gross residual, gross residual < 5 mm, gross residual < 10 mm and gross residual > 10 mm) and to avoid the usual classification (optimal and suboptimal). The goal of no gross residual disease after surgery involves more often extended surgical efforts particularly upper abdominal surgery (diaphragm stripping, splenectomy, etc.). Radical procedures without any macroscopic residual disease have been shown to be safe and potentially beneficial to patients.

Report this publication

Statistics

Seen <100 times